Pathways' Pick of the Week: FDA Mulls Robotics Risk-Benefit

article image
ARTICLE SUMMARY:

FDA considers autonomous and remote robots. Excerpted from Pathways Picks November 11: Robots, Remote Monitoring, EU Standards, and AI Picks.

FDA is asking for input on methods for gauging benefit and risk of robotic medical devices that operate with some level of autonomy or via remote teleoperation in a discussion paper posted November 6. The paper precedes a two-day workshop on the topic that will be held December 2 and 3 at FDA’s Maryland headquarters and virtually. “FDA is seeking to develop a regulatory approach that would rigorously and appropriately mitigate risks while championing the meaningful benefits these technologies offer,” the agency writes in the discussion paper, requesting written comments by January 5. FDA also published a draft guidance on more conventional robot-assisted surgical devices in September.

Continue reading Pathways Picks here.
×



Articles from David Filmore:

Regulatory & Reimbursement

Medtech and the Midterms: What to Watch as Power Shifts in DC

As Democrats get set to take control of both chambers of Congress, medtech looks for reauthorization of FDA user fees and more. The power shift in Washington, DC is significant, but its impact on medtech is unpredictable.

Read Article